Literature DB >> 26522045

Increasing orthodontic and orthognathic surgery treatment efficiency with a modified surgery-first approach.

Flavio Uribe1, Sachin Agarwal2, David Shafer3, Ravindra Nanda4.   

Abstract

This case report describes the treatment of a 33-year-old white man who had a skeletal Class III and dental Class II subdivision malocclusion caused by a retrognathic maxilla, with severe maxillary crowding, a highly placed maxillary left canine, mild mandibular crowding, and a bilateral posterior crossbite. Treatment was performed with a modified surgery-first approach, which included a short presurgical alignment phase for the correction of the significant maxillary crowding while controlling the incisal angulation, followed by LeFort I maxillary advancement surgery. The short presurgical orthodontic phase aimed at eliminating the anterior dental interferences before the maxillary advancement, and the use of the inherent increased bone turnover in the postsurgical phase helped to reduce the total orthodontic treatment time to 12 months. Pleasing esthetic results and a good functional occlusion were achieved.
Copyright © 2015 American Association of Orthodontists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26522045     DOI: 10.1016/j.ajodo.2014.10.038

Source DB:  PubMed          Journal:  Am J Orthod Dentofacial Orthop        ISSN: 0889-5406            Impact factor:   2.650


  3 in total

1.  Surgery-first: a new approach to orthognathic surgery.

Authors:  F DE Nuccio; F DE Nuccio; M M D'Emidio; S Pelo
Journal:  Oral Implantol (Rome)       Date:  2017-02-14

2.  Open bite in adult patients.

Authors:  Carlos Alberto Estevanell Tavares; Susiane Allgayer
Journal:  Dental Press J Orthod       Date:  2019-11-11

3.  Combining a digital design-mediated surgery-first approach and clear aligners to treat a skeletal Class III defect for aesthetic purposes: a case report.

Authors:  Lei Kong; Xinqiang Liu; Jie Zhang
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.573

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.